Wen, Patrick Y.

AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients

Batchelor, T. T., Sorensen, A. G., di Tomaso, E., Zhang, W.-T., Duda, D. G., Cohen, K. S., Kozak, K. R., Cahill, D. P., Chen, P.-J., Zhu, M., et al. (2007) · Cancer Cell

Angiogenesis and VEGF in CancerGlioma Diagnosis and Treatment

Cited by 1,769

Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial

Keskin, D. B., Anandappa, A. J., Sun, J., Tirosh, I., Mathewson, N. D., Li, S., Oliveira, G., Giobbie-Hurder, A., Felt, K., Gjini, E., et al. (2019) · Nature

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 1,432

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma

Cloughesy, T. F., Mochizuki, A. Y., Orpilla, J. R., Hugo, W., Lee, A. H., Davidson, T. B., Wang, A. C., Ellingson, B. M., Rytlewski, J. A., Sanders, C. M., et al. (2019) · Nature Medicine

Glioma Diagnosis and TreatmentCancer Immunotherapy and Biomarkers

Cited by 1,382

Exciting New Advances in Neuro-Oncology: The Avenue to a Cure for Malignant Glioma

Van Meir, E. G., Hadjipanayis, C. G., Norden, A. D., Shu, H. K., Wen, P. Y., & Olson, J. J. (2010) · CA: A Cancer Journal for Clinicians

Glioma Diagnosis and TreatmentAngiogenesis and VEGF in Cancer

Cited by 1,372

Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions

Wen, P. Y., Weller, M., Lee, E. Q., Alexander, B. M., Barnholtz-Sloan, J. S., Barthel, F. P., Batchelor, T. T., Bindra, R. S., Chang, S. M., Chiocca, E. A., et al. (2020) · Neuro-Oncology

Glioma Diagnosis and TreatmentOvarian cancer diagnosis and treatment

Cited by 1,168

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma

Mellinghoff, I. K., van den Bent, M. J., Blumenthal, D. T., Touat, M., Peters, K. B., Clarke, J., Mendez, J., Yust-Katz, S., Welsh, L., Mason, W. P., et al. (2023) · New England Journal of Medicine

Glioma Diagnosis and TreatmentAcute Myeloid Leukemia Research

Cited by 814

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors

Patnaik, A., Rosen, L. S., Tolaney, S. M., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Hilton, J. F., et al. (2016) · Cancer Discovery

Advanced Breast Cancer TherapiesPI3K/AKT/mTOR signaling in cancer

Cited by 743

Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma

Batchelor, T. T., Duda, D. G., di Tomaso, E., Ancukiewicz, M., Plotkin, S. R., Gerstner, E., Eichler, A. F., Drappatz, J., Hochberg, F. H., Benner, T., et al. (2010) · Journal of Clinical Oncology

Glioma Diagnosis and TreatmentAngiogenesis and VEGF in Cancer

Cited by 520

An LXR Agonist Promotes Glioblastoma Cell Death through Inhibition of an EGFR/AKT/SREBP-1/LDLR–Dependent Pathway

Guo, D., Reinitz, F., Youssef, M., Hong, C., Nathanson, D., Akhavan, D., Kuga, D., Amzajerdi, A. N., Soto, H., Zhu, S., et al. (2011) · Cancer Discovery

Cancer, Lipids, and MetabolismGlioma Diagnosis and Treatment

Cited by 452

EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy

Guo, D., Prins, R. M., Dang, J., Kuga, D., Iwanami, A., Soto, H., Lin, K. Y., Huang, T. T., Akhavan, D., Hock, M. B., et al. (2009) · Science Signaling

Cancer, Lipids, and MetabolismGlioma Diagnosis and Treatment

Cited by 351

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

Subbiah, V., Kreitman, R. J., Wainberg, Z. A., Gazzah, A., Lassen, U., Stein, A., Wen, P. Y., Dietrich, S., de Jonge, M. J. A., Blay, J.-Y., et al. (2023) · Nature Medicine

Melanoma and MAPK PathwaysGastrointestinal Tumor Research and Treatment

Cited by 343

Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours

Horbinski, C., Berger, T., Packer, R. J., & Wen, P. Y. (2022) · Nature Reviews Neurology

Glioma Diagnosis and TreatmentTuberous Sclerosis Complex Research

Cited by 312

Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib

Jackman, D. M., Holmes, A. J., Lindeman, N., Wen, P. Y., Kesari, S., Borras, A. M., Bailey, C., de Jong, F., Jänne, P. A., & Johnson, B. E. (2006) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsColorectal and Anal Carcinomas

Cited by 260

Novel anti-angiogenic therapies for malignant gliomas

Norden, A. D., Drappatz, J., & Wen, P. Y. (2008) · The Lancet Neurology

Angiogenesis and VEGF in CancerGlioma Diagnosis and Treatment

Cited by 246

Phase I Study of GRN1005 in Recurrent Malignant Glioma

Drappatz, J., Brenner, A., Wong, E. T., Eichler, A., Schiff, D., Groves, M. D., Mikkelsen, T., Rosenfeld, S., Sarantopoulos, J., Meyers, C. A., et al. (2013) · Clinical Cancer Research

Glioma Diagnosis and TreatmentNanoparticle-Based Drug Delivery

Cited by 190

Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications

Boire, A., Brandsma, D., Brastianos, P. K., Le Rhun, E., Ahluwalia, M., Junck, L., Glantz, M., Groves, M. D., Lee, E. Q., Lin, N., et al. (2019) · Neuro-Oncology

Brain Metastases and TreatmentCancer Genomics and Diagnostics

Cited by 183

Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2 -Amplified and TP53 Wild-type Glioblastomas

Verreault, M., Schmitt, C., Goldwirt, L., Pelton, K., Haidar, S., Levasseur, C., Guehennec, J., Knoff, D., Labussière, M., Marie, Y., et al. (2016) · Clinical Cancer Research

Cancer-related Molecular PathwaysGlioma Diagnosis and Treatment

Cited by 114

Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate

Stevens, M. M., Maire, C. L., Chou, N., Murakami, M. A., Knoff, D. S., Kikuchi, Y., Kimmerling, R. J., Liu, H., Haidar, S., Calistri, N. L., et al. (2016) · Nature Biotechnology

Microfluidic and Bio-sensing TechnologiesCancer Cells and Metastasis

Cited by 106

The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?

van den Bent, M. J., French, P. J., Brat, D., Tonn, J. C., Touat, M., Ellingson, B. M., Young, R. J., Pallud, J., von Deimling, A., Sahm, F., et al. (2024) · Neuro-Oncology

Glioma Diagnosis and TreatmentAcute Myeloid Leukemia Research

Cited by 88

Mutant IDH inhibitors induce lineage differentiation in IDH-mutant oligodendroglioma

Spitzer, A., Gritsch, S., Nomura, M., Jucht, A., Fortin, J., Raviram, R., Weisman, H. R., Gonzalez Castro, L. N., Druck, N., Chanoch-Myers, R., et al. (2024) · Cancer Cell

Glioma Diagnosis and TreatmentAcute Myeloid Leukemia Research

Cited by 69

A first-in-human phase I study of the CDK4/6 inhibitor, LY2835219, for patients with advanced cancer.

Shapiro, G., Rosen, L. S., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Tolaney, S. M., Beeram, M., Rasco, D. W., Kulanthaivel, P., et al. (2013) · Journal of Clinical Oncology

Advanced Breast Cancer TherapiesCancer-related Molecular Pathways

Cited by 67

Phase 2 and biomarker study of trebananib, an angiopoietin‐blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma

Reardon, D. A., Lassman, A. B., Schiff, D., Yunus, S. A., Gerstner, E. R., Cloughesy, T. F., Lee, E. Q., Gaffey, S. C., Barrs, J., Bruno, J., et al. (2018) · Cancer

Angiogenesis and VEGF in CancerGlioma Diagnosis and Treatment

Cited by 50

Abstract CT232: clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with metastatic breast cancer

Patnaik, A., Rosen, L. S., Tolaney, S. M., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Myrand, S. P., et al. (2014) · Cancer Research

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 44

LY2835219, a novel cell cycle inhibitor selective for CDK4/6, in combination with fulvestrant for patients with hormone receptor positive (HR+) metastatic breast cancer

Patnaik, A., Rosen, L. S., Tolaney, S. M., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Myrand, S. P., et al. (2014) · Journal of Clinical Oncology

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 42